BD Recognized with Three Awards by HIRC for Supply Chain Excellence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BDX?
Source: PRnewswire
- Industry Recognition: BD has been acknowledged by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive three Member Choice Awards in Transparency, Resiliency, and Partnership, highlighting its leadership in the medical supply chain.
- Customer-Centric Approach: The awards were selected based on real-world customer experiences, showcasing BD's customer-centric strategy and transparent supply chain management, which further solidifies trust within the healthcare sector.
- Consistent Performance: BD has received the HIRC Transparency Badge for four consecutive years and the Resiliency Badge in 2025, demonstrating its ongoing commitment to enhancing supply chain transparency and continuity of patient care.
- Global Impact: As one of the world's largest pure-play medical technology companies, BD supports frontline healthcare through innovative technologies and services, delivering billions of medical products annually and positively impacting global health care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 155.730
Low
157.00
Averages
192.64
High
232.00
Current: 155.730
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through four segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems and BD Interventional. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BD Recognized with Three Awards by HIRC for Supply Chain Excellence
- Industry Recognition: BD has been acknowledged by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive three Member Choice Awards in Transparency, Resiliency, and Partnership, highlighting its leadership in the medical supply chain.
- Customer-Centric Approach: The awards were selected based on real-world customer experiences, showcasing BD's customer-centric strategy and transparent supply chain management, which further solidifies trust within the healthcare sector.
- Consistent Performance: BD has received the HIRC Transparency Badge for four consecutive years and the Resiliency Badge in 2025, demonstrating its ongoing commitment to enhancing supply chain transparency and continuity of patient care.
- Global Impact: As one of the world's largest pure-play medical technology companies, BD supports frontline healthcare through innovative technologies and services, delivering billions of medical products annually and positively impacting global health care.
See More
Analysis of Defensive Healthcare Stocks
- Importance of Economic Moats: During economic uncertainty, investors should focus on healthcare companies with wide economic moats to avoid value and safety traps, ensuring investment stability and long-term growth potential.
- Strong Financial Health: Both Becton, Dickinson and Johnson & Johnson have debt-to-equity ratios below 1 and are Dividend Kings with 54 and 64 years of annual dividend growth, demonstrating their financial resilience amid economic fluctuations.
- Demand for Medical Devices: The consistent demand for Becton, Dickinson's medical supplies and lab equipment from hospitals during both booms and busts indicates the company's stability and market demand in the medical device sector.
- Signal of Dividend Growth: Johnson & Johnson's medical technology and pharmaceutical segments possess a wide economic moat, as noted by analyst Karen Anderson, reflecting its ability to withstand risks during economic downturns.
See More
Choosing Healthcare Stocks Amid Economic Uncertainty
- Importance of Economic Moats: During economic downturns, not all healthcare stocks are recession-resistant, making it crucial to select companies with wide economic moats to ensure stable returns amid market volatility.
- Becton, Dickinson's Strength: Becton, Dickinson (BDX) stands out as a medical device company that hospitals rely on for medical supplies, lab equipment, and diagnostic products, demonstrating its strong market position during both booms and busts.
- Strong Financial Health: Both Becton, Dickinson and Johnson & Johnson (JNJ) maintain debt-to-equity ratios below 1, and their status as Dividend Kings, with 54 and 64 years of annual dividend growth respectively, underscores their financial resilience during economic fluctuations.
- Recommended Selection Criteria: When evaluating other healthcare stocks, it is advisable to use economic moats and financial health as filtering criteria to identify companies worth investing in, ensuring stable returns in uncertain economic environments.
See More
TSMC Reports 35% Revenue Growth in Q1
- TSMC's Strong Performance: TSMC reported a 35% year-over-year revenue increase in Q1, with March alone seeing a 45% surge, indicating robust demand in the semiconductor market that could help Nvidia's stock break free and join the ranks of memory stocks.
- Intel Price Target Raised: Melius Research raised Intel's price target from $58 to $75 while maintaining a buy rating, reflecting optimism about its partnerships with Elon Musk's Terafab project and Google, with CEO Lip-Bu Tan's leadership being widely acknowledged.
- UBS Downgrades ServiceNow: UBS downgraded ServiceNow from buy to hold, citing weakened confidence in its ability to withstand AI disruption, despite the stock already being down 41% year-to-date, indicating a significant shift in analyst sentiment.
- Southern Company Price Target Increased: Citi raised Southern Company's price target from $107 to $114, as analysts see growth potential amid the surge in demand for electricity driven by AI data centers, maintaining a buy rating and reflecting optimism in the utility sector.
See More
Liverty™ TIPS Stent Graft Receives CE Mark, Expanding Treatment Options
- Innovative Medical Device: BD announced that the Liverty™ TIPS Stent Graft has received CE marking, aimed at improving treatment options for patients with cirrhosis, particularly for complex conditions related to portal hypertension, marking the company's latest advancement in interventional therapies.
- Clinical Study Data: Safety and efficacy data for the Liverty™ TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, which is expected to provide crucial clinical evidence for physicians and promote widespread adoption of the device.
- Market Demand Response: With approximately 58 million people affected by cirrhosis globally, the launch of the Liverty™ TIPS Stent Graft not only addresses the urgent need for safe, effective, and adaptable treatment options but also has the potential to significantly improve long-term health outcomes for patients.
- Personalized Treatment Solutions: The stent features an adjustable diameter of 6 to 10 mm and a variety of length options, allowing physicians to tailor treatments based on individual patient physiology, thereby enhancing the safety and effectiveness of the interventions.
See More
Becton, Dickinson: A Quality Stock in a Market Crash
- Market Crash Anticipation: With the Nasdaq Composite recently entering correction territory, investor fears of a market crash are rising; while a crash is not guaranteed, it could present a prime opportunity for stock investment.
- Core Business Focus: Becton, Dickinson has spun off its diabetes care and biosciences units to concentrate on its core medtech business, which is expected to enhance sales growth and strengthen its competitive position in the market.
- Attractive Valuation: Currently, Becton, Dickinson's forward P/E stands at 12.3, significantly lower than the healthcare industry average of 16.8, suggesting that its shares could become even cheaper in a market crash, drawing more investor interest.
- Dividend Advantage: With 54 consecutive years of dividend increases, Becton, Dickinson is classified as a
See More
BD Recognized with Three Awards by HIRC for Supply Chain Excellence
- Industry Recognition: BD has been acknowledged by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive three Member Choice Awards in Transparency, Resiliency, and Partnership, highlighting its leadership in the medical supply chain.
- Customer-Centric Approach: The awards were selected based on real-world customer experiences, showcasing BD's customer-centric strategy and transparent supply chain management, which further solidifies trust within the healthcare sector.
- Consistent Performance: BD has received the HIRC Transparency Badge for four consecutive years and the Resiliency Badge in 2025, demonstrating its ongoing commitment to enhancing supply chain transparency and continuity of patient care.
- Global Impact: As one of the world's largest pure-play medical technology companies, BD supports frontline healthcare through innovative technologies and services, delivering billions of medical products annually and positively impacting global health care.
See More
Analysis of Defensive Healthcare Stocks
- Importance of Economic Moats: During economic uncertainty, investors should focus on healthcare companies with wide economic moats to avoid value and safety traps, ensuring investment stability and long-term growth potential.
- Strong Financial Health: Both Becton, Dickinson and Johnson & Johnson have debt-to-equity ratios below 1 and are Dividend Kings with 54 and 64 years of annual dividend growth, demonstrating their financial resilience amid economic fluctuations.
- Demand for Medical Devices: The consistent demand for Becton, Dickinson's medical supplies and lab equipment from hospitals during both booms and busts indicates the company's stability and market demand in the medical device sector.
- Signal of Dividend Growth: Johnson & Johnson's medical technology and pharmaceutical segments possess a wide economic moat, as noted by analyst Karen Anderson, reflecting its ability to withstand risks during economic downturns.
See More
Choosing Healthcare Stocks Amid Economic Uncertainty
- Importance of Economic Moats: During economic downturns, not all healthcare stocks are recession-resistant, making it crucial to select companies with wide economic moats to ensure stable returns amid market volatility.
- Becton, Dickinson's Strength: Becton, Dickinson (BDX) stands out as a medical device company that hospitals rely on for medical supplies, lab equipment, and diagnostic products, demonstrating its strong market position during both booms and busts.
- Strong Financial Health: Both Becton, Dickinson and Johnson & Johnson (JNJ) maintain debt-to-equity ratios below 1, and their status as Dividend Kings, with 54 and 64 years of annual dividend growth respectively, underscores their financial resilience during economic fluctuations.
- Recommended Selection Criteria: When evaluating other healthcare stocks, it is advisable to use economic moats and financial health as filtering criteria to identify companies worth investing in, ensuring stable returns in uncertain economic environments.
See More
TSMC Reports 35% Revenue Growth in Q1
- TSMC's Strong Performance: TSMC reported a 35% year-over-year revenue increase in Q1, with March alone seeing a 45% surge, indicating robust demand in the semiconductor market that could help Nvidia's stock break free and join the ranks of memory stocks.
- Intel Price Target Raised: Melius Research raised Intel's price target from $58 to $75 while maintaining a buy rating, reflecting optimism about its partnerships with Elon Musk's Terafab project and Google, with CEO Lip-Bu Tan's leadership being widely acknowledged.
- UBS Downgrades ServiceNow: UBS downgraded ServiceNow from buy to hold, citing weakened confidence in its ability to withstand AI disruption, despite the stock already being down 41% year-to-date, indicating a significant shift in analyst sentiment.
- Southern Company Price Target Increased: Citi raised Southern Company's price target from $107 to $114, as analysts see growth potential amid the surge in demand for electricity driven by AI data centers, maintaining a buy rating and reflecting optimism in the utility sector.
See More
Liverty™ TIPS Stent Graft Receives CE Mark, Expanding Treatment Options
- Innovative Medical Device: BD announced that the Liverty™ TIPS Stent Graft has received CE marking, aimed at improving treatment options for patients with cirrhosis, particularly for complex conditions related to portal hypertension, marking the company's latest advancement in interventional therapies.
- Clinical Study Data: Safety and efficacy data for the Liverty™ TIPS Stent Graft will be presented for the first time at the Society of Interventional Radiology annual meeting on April 12, 2026, which is expected to provide crucial clinical evidence for physicians and promote widespread adoption of the device.
- Market Demand Response: With approximately 58 million people affected by cirrhosis globally, the launch of the Liverty™ TIPS Stent Graft not only addresses the urgent need for safe, effective, and adaptable treatment options but also has the potential to significantly improve long-term health outcomes for patients.
- Personalized Treatment Solutions: The stent features an adjustable diameter of 6 to 10 mm and a variety of length options, allowing physicians to tailor treatments based on individual patient physiology, thereby enhancing the safety and effectiveness of the interventions.
See More
Becton, Dickinson: A Quality Stock in a Market Crash
- Market Crash Anticipation: With the Nasdaq Composite recently entering correction territory, investor fears of a market crash are rising; while a crash is not guaranteed, it could present a prime opportunity for stock investment.
- Core Business Focus: Becton, Dickinson has spun off its diabetes care and biosciences units to concentrate on its core medtech business, which is expected to enhance sales growth and strengthen its competitive position in the market.
- Attractive Valuation: Currently, Becton, Dickinson's forward P/E stands at 12.3, significantly lower than the healthcare industry average of 16.8, suggesting that its shares could become even cheaper in a market crash, drawing more investor interest.
- Dividend Advantage: With 54 consecutive years of dividend increases, Becton, Dickinson is classified as a
See More
